We are live on ! Find out more
B

Braidwell Portfolio holdings

AUM $2.7B
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-7%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.84B
AUM Growth
-$528M
Cap. Flow
-$782M
Cap. Flow %
-27.48%
Top 10 Hldgs %
40.1%
Holding
81
New
10
Increased
17
Reduced
14
Closed
17

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$67.5M
2
ARGX icon
argenx
ARGX
+$50.5M
3
NUVL
Nuvalent
NUVL
+$46.9M
4
GKOS icon
Glaukos
GKOS
+$44.8M
5
BPMC
Blueprint Medicines
BPMC
+$42.9M

Top Sells

Rank Stock Value
1
GH icon
Guardant Health
GH
+$65.6M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$43.2M
3
FNA
Paragon 28, Inc.
FNA
+$39.6M
4
BNTX icon
BioNTech
BNTX
+$35.3M
5
RGEN icon
Repligen
RGEN
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 67.44%
2 Miscellaneous 32.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VKTX icon
26
Viking Therapeutics
VKTX
$3.75B
$34.7M 1.22%
1,435,955
-43,711
-3% -$1.38M
PEN icon
27
Penumbra
PEN
$12.7B
$29.4M 1.04%
110,128
-73,700
-40% -$19.9M
BCAX
28
Bicara Therapeutics
BCAX
$1.55B
$28.2M 0.99%
2,162,803
+162,144
+8% +$2.15M
DAWN
29
DELISTED
Day One Biopharmaceuticals
DAWN
$28M 0.99%
3,536,853
-1,337,000
-27% -$14.4M
KIDS icon
30
OrthoPediatrics
KIDS
$617M
$27.3M 0.96%
1,107,770
– –
HROW icon
31
Harrow
HROW
$1.4B
$25.5M 0.89%
956,839
+49,800
+5% +$1.49M
MRVI icon
32
Maravai LifeSciences
MRVI
$1.14B
$18.5M 0.65%
8,353,287
– –
XNCR icon
33
Xencor
XNCR
$1.94B
$17.6M 0.62%
1,655,690
+1,040,159
+169% +$17.2M
ASND icon
34
Ascendis Pharma A/S
ASND
$16.3B
$16.6M 0.58%
+106,713
New +$15.2M
ORKA
35
Oruka Therapeutics
ORKA
$6.03B
$16.1M 0.57%
1,572,426
+424,750
+37% +$5.3M
MDGL icon
36
Madrigal Pharmaceuticals
MDGL
$12.3B
$16.1M 0.57%
+48,690
New +$16M
SRPT icon
37
Sarepta Therapeutics
SRPT
$2.2B
$15M 0.53%
234,500
-130,400
-36% -$13.7M
REPL icon
38
Replimune Group
REPL
$1.46B
$14.3M 0.5%
1,461,826
-15,276
-1% -$189K
RGEN icon
39
Repligen
RGEN
$9.95B
$10.4M 0.37%
81,656
-202,167
-71% -$31.1M
IRWD icon
40
Ironwood Pharmaceuticals
IRWD
$682M
$9.74M 0.34%
6,622,584
+1,182,307
+22% +$2.82M
CELC icon
41
Celcuity
CELC
$4.33B
$8.94M 0.31%
884,306
– –
CGEM icon
42
Cullinan Oncology
CGEM
$1.4B
$7.42M 0.26%
980,773
-195,400
-17% -$1.87M
CSTL icon
43
Castle Biosciences
CSTL
$1.02B
$7.31M 0.26%
+365,247
New +$9.04M
DNTH icon
44
Dianthus Therapeutics
DNTH
$5.92B
$6.81M 0.24%
375,355
-831,234
-69% -$18.3M
LUNG icon
45
Pulmonx
LUNG
$102M
$5.06M 0.18%
752,541
– –
MTSR
46
DELISTED
Metsera Inc
MTSR
$4.76M 0.17%
+175,000
New +$4.96M
AARD
47
Aardvark Therapeutics
AARD
$127M
$3.75M 0.13%
+500,000
New +$5.61M
JBIO
48
Jade Biosciences
JBIO
$1.33B
$3.62M 0.13%
41,157
– –
ZURA icon
49
Zura Bio
ZURA
$548M
$3.19M 0.11%
2,472,806
– –
BBNX
50
Beta Bionics
BBNX
$887M
$1.71M 0.06%
+140,000
New +$2.61M
1
2
3

Similar funds

CWM
Connecticut Wealth Management Farmington, Connecticut $2.7B AUM 21.91% 1-Year Est. Return
M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
BIAS
Beacon Investment Advisory Services Morristown, New Jersey $2.69B AUM 35.07% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM

Braidwell's Q1 2025 Portfolio in Review

As of Q1 2025, Braidwell held 81 positions worth $2.84B, down 16% from $3.37B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Braidwell withdrew a net $782M in Q1 2025, closing 17 positions and reducing 14 holdings. Its most notable exit was Avadel Pharmaceuticals, an estimated $43.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

Against the trend, Braidwell opened a new position in Danaher worth $63.4M.

  • Braidwell's largest Q1 2025 buy was Danaher: 309,339 shares worth $63.4M.
  • Braidwell added most to argenx in Q1 2025, an estimated $50.5M increase.
  • Braidwell's biggest Q1 2025 reduction was Guardant Health, cutting an estimated $65.6M.
  • Braidwell fully exited Avadel Pharmaceuticals in Q1 2025, selling an estimated $43.2M.
  • Braidwell's ten largest holdings make up 40% of its $2.84B portfolio in Q1 2025.
  • Braidwell opened 10 new positions and closed 17 in Q1 2025.
  • Braidwell's portfolio value fell 16% quarter-over-quarter to $2.84B.

Based on Braidwell's 13F filing for Q1 2025, filed 15 May 2025.